Due: April 30, 2026
Through the Rapid Antibody Production for Immunoassay Diagnostics (RAPID) RPP, BARDA seeks to support advanced research and development of rapid antibody and other protein-based molecular recognition reagent generation platforms to enable timely production of immunoassay-ready reagents for diagnostic use. The objective is to establish flexible, end-to-end systems capable of generating high-performance binders against known and emerging biological threats, with the goal of significantly compressing development timelines from pathogen sequence to assay-ready reagents—ideally within weeks.
Responding to this opportunity requires membership in the Rapid Response Partnership Vehicle (RRPV). This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.